Unlock instant, AI-driven research and patent intelligence for your innovation.

Drug and method for the prophylaxis of HIV infection and for the prophylaxis and treatment of diseases caused by or associated with HIV, including AIDS

A medicine and disease technology, applied in chemical instruments and methods, antiviral agents, pharmaceutical formulas, etc., to achieve the effect of preventing HIV infection and high curative effect

Inactive Publication Date: 2013-07-17
奥列格·伊里奇·爱泼斯坦
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, this agent is ineffective neither in the prevention of HIV infection nor in the prevention and treatment of various diseases caused by HIV or HIV-related diseases (including AIDS)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0140] The antiretroviral effect of the claimed agent was investigated by inhibiting HIV replication in cultures of human peripheral blood mononuclear cells infected with the HIV-1-LAI strain in vitro. The effectiveness of inhibiting HIV replication was evaluated according to the content of HIV's main nucleocapsid protein p24 in the supernatant.

[0141] The experimental research is to use affinity-purified anti-tumor necrosis factor-α rabbit polyclonal antibody, which is prepared by a professional biotechnology company. It is a very low-dose, active-enhanced form of anti-tumor necrosis The basis of the factor-α antibody aqueous solution, which is produced using homeopathic technology through the following steps: the initial matrix solution (concentration 2.5mg / ml) is heavily diluted (over-dilution) 100 12 , 100 30 , 100 50 It is equivalent to a mixture of Hundred Times Homeopathic Diluent C12, C30, C50 (hereinafter referred to as anti-TNFα ESD AB). Human peripheral blood mononuc...

Embodiment 2

[0149] The antiretroviral effect of the claimed agent was investigated by inhibiting HIV replication in cultures of human peripheral blood mononuclear cells infected with the HIV-1-LAI strain in vitro. The effectiveness of inhibiting HIV replication was evaluated according to the content of HIV's main nucleocapsid protein p24 in the supernatant.

[0150] The experimental research is to use affinity-purified anti-CD8 rabbit polyclonal antibody, which is prepared by a professional biotechnology company. It is the basis for preparing an extremely low-dose, activity-enhanced form of anti-CD8 antibody aqueous solution. The aqueous solution is produced using homeopathic technology through the following steps: the initial matrix solution (concentration 2.5 mg / ml) is heavily diluted 100 12 , 100 30 , 100 50 It is equivalent to a mixture of Hundred Times Homeopathic Diluent C12, C30, C50 (hereinafter referred to as anti-CD8 ESD AB).

[0151] Human peripheral blood mononuclear cells infected...

Embodiment 3

[0158] Using human peripheral blood mononuclear cells infected with HIV-1-LAI strain in vitro, the anti-interferon α rabbit polyclonal antibody (affinity-purified) water dilution solution of ultra-low dose (ULD), activity-enhanced form The retroviral activity was evaluated, and the water dilution was produced by the following steps: the initial matrix solution (concentration of 2.5 mg / ml) was largely diluted 100 12 , 100 30 , 100 50 It is equivalent to a mixture of Hundreds of Homeopathic Diluents C12, C30, and C50 (hereinafter referred to as anti-IFN-α ESD AB). Azidothymidine was used as a control formulation.

[0159] With the aid of Ficoll-Hypaque density gradient centrifugation, human peripheral blood mononuclear cells were separated from the blood of seronegative healthy donors. The cells were activated with 1mcg / ml phytogemmaglyutin P and 5ME / ml recombinant human interleukin-2 for 3 days.

[0160] An inoculum of 50 μl of the HIV-1-LAI strain equivalent to a dose of 100 TCID5...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
particle diameteraaaaaaaaaa
Login to View More

Abstract

The drug for the prophylaxis of HIV infection and for the prophylaxis and treatment of diseases caused by or associated with HIV, including AIDS, comprises an activated, potentiated form of antibodies to a protein or peptide of the immune system which interacts with the HIV or has a content and / or functional activity which changes in connection with an HIV infection. Furthermore, in the method for the prophylaxis of HIV infection and for the prophylaxis and treatment of diseases caused by or associated with HIV, including AIDS, use is made of an activated, potentiated form of antibodies to an antigen, namely a protein or peptide of the immune system, which interacts with the HIV or has a content and / or functional activity which changes in connection with an HIV infection.

Description

Technical field [0001] The invention belongs to the field of medicine and can be used to effectively prevent HIV infection, and prevent and treat diseases caused by HIV and HIV-related diseases (including AIDS). Background technique [0002] The prior art includes agents (RU2192888C1, A61K39 / 395, 20.11.2002) for the treatment of infectious diseases (including viral diseases) based on the active form of very low doses of anti-interferon antibodies. However, this agent is not only ineffective for the prevention of HIV infection, but also for the prevention and treatment of various diseases caused by HIV or HIV-related diseases (including AIDS). Summary of the invention [0003] The present invention is directed to the development of a compound medicament without obvious side effects, which makes it possible to effectively prevent HIV infection and prevent and effectively treat diseases caused by HIV or HIV-related diseases (including infections and infections in HIV-positive subject...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/00A61P31/18
CPCC07K16/241A61K39/00A61K41/0004A61K2039/545C07K16/28C07K16/2815C07K16/249C07K2317/70A61P31/12A61P31/18A61P37/04A61K39/395A61K39/39533A61K39/3955A61K39/39566
Inventor 奥列格·伊里奇·爱泼斯坦谢尔盖·亚历山德罗维奇·塔拉索夫
Owner 奥列格·伊里奇·爱泼斯坦